{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:21:01Z","timestamp":1787509261790,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Systemic chemotherapy is the standard treatment for unresectable intrahepatic cholangiocarcinoma (iCCA); however, its efficacy remains limited. We report a clinically valuable case of a 57-year-old woman with advanced unresectable iCCA characterized by high microsatellite instability (MSI-high) and major vascular invasion. The patient presented with purpura and was diagnosed with MSI-high iCCA with intravascular tumor extension reaching the right atrium and regional lymph node metastases. Combination therapy with gemcitabine, cisplatin, and durvalumab (GCD therapy) was initiated, resulting in a 56% reduction in tumor size after eight cycles. To enhance local tumor control, proton beamtherapy (3.3 Gy \u00d7 22 fractions) was added, which was completed without adverse events. The patient subsequently received durvalumab maintenance therapy, followed by pembrolizumab. Although there was minimal growth of lymph node and pulmonary metastases, no regrowth of the intrahepatic primary tumor was observed for 18 months after PBT. This case illustrates the potential clinical value of combining GCD therapy with proton beam therapy for MSI-high, unresectable iCCA with major vascular invasion. The combination achieved systemic disease control and durable local control without significant toxicity.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1685944","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:04:52Z","timestamp":1761199492000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effective control in MSI-high unresectable intrahepatic cholangiocarcinoma treated with gemcitabine\/cisplatin\/durvalumab and proton beam therapy: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Takuto","family":"Nosaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000522403","article-title":"Liver cancer study group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma","volume":"11","author":"Kubo","year":"2022","journal-title":"Liver Cancer"},{"key":"B5","article-title":"Analysis of microsatellite instability, K-ras gene mutation and P53 protein overexpression in intrahepatic cholangiocarcinoma","volume":"49","author":"Isa","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase ii keynote-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.2710","article-title":"Multi-institutional phase ii study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717x-9-26","article-title":"Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma","volume":"9","author":"Makita","year":"2014","journal-title":"Radiat Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12843","article-title":"Proton beam therapy for unresectable intrahepatic cholangiocarcinoma","volume":"30","author":"Ohkawa","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000531376","article-title":"Proton beam therapy for intrahepatic cholangiocarcinoma: A multicenter prospective registry study in Japan","volume":"13","author":"Mizumoto","year":"2024","journal-title":"Liver Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (Topaz-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4588-20","article-title":"Microsatellite instability-high intrahepatic cholangiocarcinoma with portal vein tumor thrombosis successfully treated with pembrolizumab","volume":"59","author":"Naganuma","year":"2020","journal-title":"Intern Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000530134","article-title":"Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases","volume":"12","author":"De","year":"2023","journal-title":"Liver Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13014-019-1451-5","article-title":"Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy","volume":"14","author":"Shimizu","year":"2019","journal-title":"Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717x-8-292","article-title":"Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma","volume":"8","author":"Kim","year":"2013","journal-title":"Radiat Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-08142-9","article-title":"Hypofractionated radiation therapy for unresectable\/locally recurrent intrahepatic cholangiocarcinoma","volume":"27","author":"Smart","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1273962","article-title":"Case report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"Easl-ilca clinical practice guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13483","article-title":"Switching administration of anti-pd-1 and anti-pd-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review","volume":"11","author":"Kitagawa","year":"2020","journal-title":"Thorac Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: asco guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-Kb to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00153","article-title":"Radiation as an immunological adjuvant: current evidence on dose and fractionation","volume":"2","author":"Demaria","year":"2012","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.12.019","article-title":"Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: A comparative analysis of proton versus photon therapy","volume":"156","author":"Kim","year":"2021","journal-title":"Radiother Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/med4.27","article-title":"Crosstalk between cancer cells and the nervous system","volume":"1","author":"Huang","year":"2023","journal-title":"Med Adv"},{"key":"B28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.20517\/cdr.2024.97","article-title":"The role and clinical applications of exosomes in cancer drug resistance","volume":"7","author":"Pan","year":"2024","journal-title":"Cancer Drug Resistance"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/inmd.20250016","article-title":"Patient-derived xenograft models in pan-cancer: from bench to clinic","volume":"3","author":"Li","year":"2025","journal-title":"Interdiscip Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1685944\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:04:53Z","timestamp":1761199493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1685944\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1685944"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1685944","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"article-number":"1685944"}}